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Abstract 33 
Purpose: Coronavirus Disease 2019 (COVID-19) is a global pandemic affecting hospital systems 34 
and the availability of resources for surgical procedures. Our aim is to provide guidance for 35 
urologists to help prioritize urologic cancer surgeries. 36 
Material and Methods: We reviewed published literature on bladder cancer, upper tract urothelial 37 
carcinoma (UTUC), penile cancer, testis cancer, prostate cancer, renal cancer, and adrenal 38 
cancer. 39 
Results:  For muscle invasive bladder cancer (MIBC), delays should be less than roughly 10 40 
weeks and neoadjuvant chemotherapy should be considered. For non-MIBC, patients should be 41 
counseled appropriately based on risk and intravesical therapies can continue. UTUC should also 42 
be treated with minimal delays for high risk patients, especially with ureteral tumors. Surgery for 43 
T1 renal cancers when indicated can be delayed until adequate resources are available.  Patients 44 
with T2 renal cancer should be considered for early surgery if there are unfavorable pre-45 
operative characteristics. Higher stage renal tumors should be considered for early surgery. Early 46 
multi-disciplinary approach is recommended for metastatic renal cancers. High risk prostate 47 
cancer may need preferential treatment and consideration of neoadjuvant hormonal therapy. 48 
Penile cancer can have worse sexual or oncologic outcome with prolonged surgical delay. 49 
Likewise, adrenal cancer is aggressive and needs early surgical treatment. Testicular cancer 50 
should be treated in a timely manner with surgery or chemotherapy, as indicated. 51 
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Conclusions: This review should further assist urologists in recognizing patients with potentially 52 
aggressive tumor biology that warrant early treatment. 53 
Introduction 54 
Severe acute respiratory syndrome coronavirus – 2 (SARS-CoV-2) can induce a severe 55 
respiratory compromise with rapid human-to-human transmission stressing entire hospital 56 
systems. In order to conserve resources and prevent further spread of COVID-19, the CDC and 57 
hospital systems have requested physicians to reconsider non-urgent procedures. Here, we aim to 58 
discuss the effect of COVID-19 on urologic cancers, specifically regarding anticipated delays in 59 
surgical treatment. 60 
Background 61 
COVID-19 is highly transmissible and can cause respiratory issues requiring ventilation, 62 
ICU care, and death. Epidemiologic factors and high rates of hospitalization for patients with 63 
COVID-19 have resulted in widespread cancellation of elective surgical procedures in favor of 64 
prioritizing urgent procedures. 65 
In response to COVID-19, recommendations for prioritizing cases have been published1. 66 
With reopening of operating rooms, region-specific factors should guide treatment as resources 67 
and COVID-19 surges vary across the world. Throughout this process, urologists should assist in 68 
appropriate timing of treating urologic cancers. Thus, our aim is to provide further guidance by 69 
demonstrating the potential biases in the literature and add to published recommendations. 70 
Tumor biology may dictate treatment that deviates from these recommendations and should be 71 
discussed with patients. 72 
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Bladder Cancer 73 
Several publications have discussed potential consequences in delaying extirpative 74 
surgery for muscle invasive bladder cancer (MIBC). Boeri et al. studied their cohort of MIBC 75 
patients (cT2-T4) and found that a delay greater than 10 weeks after the last neoadjuvant 76 
chemotherapy (NAC) cycle led to worse outcomes for cancer-specific and overall mortality. 77 
Delays in surgery increased mortality even when accounting for age, gender, and extent of 78 
disease2. Similarly, in patients that only underwent radical cystectomy without NAC, Sanchez-79 
Ortiz et al. found that even after adjusting for pathologic aggressiveness, patients who were 80 
delayed longer than 12 weeks had worse survival – 3-year estimated survival for the delayed 81 
group was 34.9%±13.5% compared to 62.1%±4.5% for patients receiving surgery before 12 82 
weeks3. Other groups had similar findings that a delay in surgery led to worse outcomes when 83 
greater than 90 days passed from diagnosis or NAC to surgery4. 84 
Despite these studies suggesting the importance of performing cystectomy in a timely 85 
manner, Alva et al. demonstrated that there was no survival benefit to earlier cystectomy (<10 86 
weeks after last dose of NAC)5. The study also found no difference between groups of patients 87 
that were delayed 12 weeks, but 10 weeks was used as a cut off to add confidence to their 88 
conclusions. This group found that pathologic stage was a factor in overall survival but could not 89 
find that actual timing of radical cystectomy played a role in survival outcomes. Park et al. also 90 
published a retrospective review that found no significantly detrimental impact to delaying 91 
surgery until 28 weeks after the TURBT diagnosis6. Furthermore, a 6-week delay in NAC 92 
initiation or a 22-week delay from NAC initiation to RC did not affect survival (about 10-12 93 
weeks from NAC completion to RC). This group found that inferior outcomes were related to the 94 
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presence of extravesical disease. In patients that did not undergo NAC, Nielsen et al. also found 95 
that interval from diagnosis to radical cystectomy of 3 months was not necessarily associated 96 
with progression and worse survival outcomes7. 97 
Patients with variant histology on final surgical pathology after cystectomy, and patients 98 
experiencing an 8 week delay had worse overall survival8. Within the same study, however, 99 
patients with clinical variants (diagnosed at TURBT) had 12 weeks as the cutoff for survival 100 
differences. This study did not specify any differences between variant histology. 101 
NAC should be carefully discussed with patients by their medical oncologist as there may 102 
be associated risks with exposure and decreased immunity to COVID-19. Audenet et al. found 103 
that delays from time of TURBT to NAC by more than 8 weeks, without delay from NAC to 104 
radical cystectomy, can affect the disease course9. After a median follow up time of 45.7 months, 105 
no significant changes in overall survival were noted, but patients that had a delay to NAC were 106 
more likely to be upstaged on final surgical pathology. RFS or CSS were not calculated in this 107 
study. 108 
For diagnosing bladder cancer, Wallace et al. found that delays occur between onset of 109 
symptoms and diagnosis. This study divided delay times between onset of symptoms to general 110 
practitioner (GP), GP to specialist, and then time to the OR. The delay from onset of symptoms 111 
to GP greater than 14 days played a significant role in survival outcomes because these patients 112 
consequently had higher stage tumors and worse survival outcomes of 5% at 5 years compared to 113 
those that did not have any delay10.  During this pandemic, patients likely will experience a delay 114 
in seeing a GP due to widely issued stay-at-home orders. This stresses the importance of 115 
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continuing to perform screening cystoscopy, during the pandemic, for patients suspected to have 116 
bladder cancer in order to accurately identify the aggressiveness of disease. 117 
For NMIBC, the literature is limited for the effects of delaying intravesical therapy. 118 
However, studies have compared early versus late cystectomy for high risk NMIBC patients and 119 
have found that prolonged delays can affect survival. Jager et al. studied effects on delayed 120 
cystectomy for high risk NMIBC and found that patients that were delayed for ≥ 13 months may 121 
start to see an effect on CSS11. The survival outcomes for aggressive NMIBC is likely dependent 122 
on the tumor biology rather than specific timing delays. Hautmann et al. studied specifically T1 123 
G3, high risk disease and found that CSS was 83.9% vs 74.8% at 5 years and at 10 years 78.9% 124 
versus 64.5% in favor of immediate cystectomy (within 90 days) compared to deferred 125 
cystectomy (second TURBT, BCG administration and repeat TURBT), which is likely result of 126 
the lack of response to therapy12. And for patients with initial response to intravesical therapy by 127 
looking at patients that had recurrent NMIBC disease, patients that received one additional 128 
salvage intravesical treatment were able to retain their bladder for 1.7 years longer without any 129 
survival detriment13. Results with deferred cystectomy is highly variable due to the differences in 130 
tumor biology and responsiveness to intravesical therapy and it is hard to generalize for the 131 
purposes of this review. For high-risk NMIBC that are considering cystectomy, delays 132 
experienced due to the COVID-19 pandemic should pose minimal risk to survival outcomes, but 133 
urologists should still carefully assess the aggressiveness of each patient’s individual cancer to 134 
determine appropriate timing of cystectomy. 135 AC
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For NMIBC, patients requiring intravesical therapy, especially induction dose, for 136 
intermediate or high-risk NMIBC should still be considered with the clear benefits of intravesical 137 
therapy. 138 
Discussion: A systematic review and meta-analysis discussing potential delays in treating 139 
MIBC ultimately found that an acceptable length of delay could not be determined, but 140 
recognized that delays do cause a detrimental effect on overall survival4. Based on these past 141 
studies, patients with MIBC should consider NAC and should undergo radical cystectomy within 142 
10-12 weeks either after TURBT without NAC or after NAC completion. However, as many of143 
these studies demonstrated issues with delaying surgery in terms of disease progression, MIBC 144 
especially those that are extravesical may be prioritized.  For new patients, surveillance 145 
cystoscopy to assess risk and burden of disease is still important and should continue during this 146 
pandemic (Table 1). Finally, the literature on delaying intravesical therapy in lacking, but they 147 
should continue with proper counseling. 148 
Upper Tract Urothelial Cancer (UTUC) 149 
Literature review of UTUC demonstrated that delay in surgical time likely does affect 150 
overall survival outcomes in higher risk cases. Lee et al. found that surgical delay of greater than 151 
1 month was not an independent prognostic factor when all 138 patients with upper tract 152 
urothelial carcinoma were included in their survival curves14. However, once the analysis was 153 
further sub-categorized by location to renal pelvic tumor and ureteral tumors, tumors in the 154 
ureter had worse prognosis for patients that delayed surgery by one month -CSS (87.9% vs 155 
54.5%) and RFS (85.6% vs 60.7%). Of note, both low-grade and high-grade urothelial carcinoma 156 
were included in their analysis. A study done by Waldert et al. found that a 3 month delay to 157 
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radical nephroureterectomy (RNU) may not necessarily have worse survival outcomes at 3 and 5 158 
years15. This study treated delay time as a continuous variable as well and found that longer time 159 
to surgery was correlated with advancing pathologic stage, higher tumor grade, concomitant CIS, 160 
tumor necrosis, infiltration, worse CSS, and increased likelihood of recurrence. This study 161 
performed a subgroup analysis with muscle invasive disease (≥ pT2), which demonstrated that 162 
there was no significant difference in survival outcomes (RFS and CSS) using 3 months as a 163 
cutoff point. However, once again they noted that these muscle invasive patients experiencing a 164 
delay in surgery had worsening surgical pathology (advanced stage, higher grade, infiltrative 165 
tumor architecture, and lymphovascular invasion). Nison et al. also found similar findings with 166 
no significant difference with survival outcomes CSS, RFS, and metastasis free survival (MFS) 167 
in a muscle invasive subgroup. Their group compared patients that had median time of 62 days 168 
compared to 47 days until RNU16. Sundi et al. studied the consequences of a 3-month delay prior 169 
to RNU and did not find any negative effect with respect to RFS, DSS, and OS. Patients in this 170 
cohort had approximately 79% high risk patients. Even after excluding patients from the delayed 171 
group that had undergone NAC, there was no decrement in 5- year DSS (71.6% vs 81.5%) and 172 
OS (61.3% vs 77%) among those waiting longer than 3 months. In this secondary analysis, of the 173 
delayed group (54 patients) – 27 had NAC and 9 more patients were delayed from being on 174 
surveillance and endoscopic management, meaning that a portion of patients that were delayed 175 
likely had lower risk disease17. 176 
Discussion: It has been well established that low grade UTUC is less aggressive and safe 177 
to keep on surveillance and undergo endoscopic management. Until burden and risk of disease is 178 
determined, similarly to bladder cancer, patients should undergo thorough evaluation with 179 
endoscopy. In evaluating these studies, patients with high-risk disease may be preferentially 180 
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treated as many studies were retrospective and preferentially treated aggressive patients sooner 181 
(<3 months). Patient with tumor location in the ureter may also require limited delay (Table 1). 182 
While some studies have shown efficacy with NAC and could delay surgery, those patients in 183 
whom immunosuppression is of concern, adjuvant therapy after early surgery may be offered 184 
with success18. 185 
Renal Cancer 186 
For small renal masses (≤ 4 cm), active surveillance has become an acceptable standard 187 
of care. These patients are typically followed to monitor growth kinetics to determine 188 
intervention, and typical follow-up during active surveillance was in 6-month to 12-month 189 
intervals. Uzosike et al. noted in their evaluation of patients in the Delayed Intervention and 190 
Surveillance for Small Renal Masses (DISSRM) trial that no patients on active surveillance died 191 
from kidney cancer or developed metastatic disease19. Other studies looking at the SEER 192 
database have found a small rate (<4%) of metastasis for masses <5cm20. 193 
For larger renal masses (≥ 4cm), Mano et al. evaluated data from 1,278 patients in a 194 
retrospective analysis of which 267 (21%) patients had surgical wait times (SWT) greater than 3 195 
months. Median mass size was 6.2 cm (6.5 cm for SWT ≤ 3 mo. and 5.7 cm for SWT > 3 mo.)21.196 
On analysis, SWT were not associated with disease upstaging, recurrence, or cancer specific 197 
survival. Stec et al. also retrospectively analyzed a cohort of patients with a mean renal mass size 198 
of 6.4 ± 4.4 cm. and found no differences in overall survival (OS), cancer-specific survival 199 
(CSS), or recurrence-free survival (RFS) when delaying surgery for patients and accounting for 200 
differences in tumor grade and pathology22. Their group found that 5-year OS, CSS, or RFS was 201 
determined based on the staging of disease, histology, tumor grade, and extent of spread at 202 
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presentation. RFS was found to be worse in patients who underwent surgery within a month 203 
likely because larger, more aggressive-appearing masses were preferentially treated. In a study 204 
by Kim et al., similar findings were shown in a retrospective review of 1,732 patients who 205 
underwent surgery for RCC for masses with a mean size of 8.9±2.6 cm that were at least stage 206 
T2a23. Their group found that SWT of 1-3 months compared to SWT of <1 month was not an 207 
independent predictor of pathological upstaging, RFS, or CSS. This study also discussed the 208 
impact of SWT on symptomatic patients as they had higher clinical and pathologic stages, but 209 
there was no association between SWT and pathologic upstaging, CSS, or RFS. Considering the 210 
literature, these studies were retrospective in nature and clinicians appeared to selectively and 211 
more urgently operate on patients with more aggressive-appearing renal tumors. Also with 212 
symptomatic patients, Lee et al. found that patients with flank pain, hematuria, varicocele, 213 
constitutional symptoms correlated to aggressive histology and worse survival outcomes24. DSS 214 
was 91% at 5 years for non-symptomatic patients versus 68% at 5 year for symptomatic patients. 215 
Thus, RCC (≥T2) can be further risk-stratified to determine urgency of treatment. To assist in 216 
predicting which renal masses are more aggressive, nomograms can help predict high-risk, high-217 
grade pathology that requires more urgent attention25. Renal mass biopsy may provide some 218 
benefit, clear cell RCC, papillary RCC, and chromophobe typically correctly identify the 219 
pathology, however Fuhrman grade is less concordant. Abel et al. also studied concordance for 220 
high risk pathological features and found that 31.7% of patients had the same Fuhrman grade as 221 
final path and 67.9% had same concordance if stratified by low and high risk26 . 222 
Metastatic renal cell carcinoma that is under consideration for cytoreductive nephrectomy 223 
(CN) should consider neoadjuvant therapy based on early results. Deferring immediate CN may 224 
not cause any harm in survival outcomes based on the SURTIME and CARMENA trials27, 28. 225 
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The SURTIME trial accrued fewer patients than the CARMENA trial, but demonstrated that 226 
there was no significant difference in survival for patients that deferred CN compared to patients 227 
that underwent upfront CN27. Of the 48 patients that deferred CN, 14 patients went against 228 
protocol and 6 underwent surgery. When these off-protocol patients were studied, the deferred 229 
CN patients seemed to have improved overall survival. There still appears to be some role in CN, 230 
especially in those patients that have some response to neoadjuvant immunotherapy which can 231 
also help to delay surgery. For more localized renal cell carcinomas, Rini et al. also demonstrated 232 
that Pazopanib can be administered for 8-16 weeks prior to surgery to decrease tumor size in a 233 
Phase II trial (92% of patients)29. 234 
Discussion: Patients with renal masses (≥T2) should undergo careful evaluation, as these 235 
patients still carry a risk for metastasis. These studies looking at delaying surgery are 236 
retrospective and patients with high-risk features typically had operations without significant 237 
delay, which may account for the similar survival outcomes. Priority should be given to those 238 
with aggressive features– imaging findings, possible renal mass biopsy results, symptoms etc. 239 
(Table 1). For those with metastatic kidney cancer, neoadjuvant options should be discussed with 240 
medical oncologists for immune risks with COVID-19. 241 
Prostate Cancer 242 
Delaying radical prostatectomy (RP) for prostate cancer depends heavily on the clinical 243 
staging. Meunier et al. published a retrospective analysis of 513 patients by selecting 244 
biochemical recurrence (BCR) as the primary endpoint30. The study found that for surgical delay, 245 
there was no threshold for patients with Gleason 6 (3+3), a 90-day threshold for Gleason 7, and a 246 
60-day threshold for Gleason ≥ 8 cancers. Other studies using biochemical recurrence as the247 
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endpoint, found 3 months to 6 months as a cut-off point31, 32. Similar findings were found for 248 
patients considering radiation therapy, where patients had a higher likelihood of PSA failure for 249 
patients with high risk disease after a 2.5 month period, which is similar to the outcomes for 250 
surgical delay33. 251 
Other studies have suggested that it is possible to delay surgery for longer periods of 252 
time. Recently, Ginsburg et al. performed a retrospective review of the National Cancer Database 253 
and found that delays up to 12 months did not have worse oncological outcomes (adverse 254 
pathology, upstaging on RP, or secondary treatment) for intermediate and high-risk prostate 255 
cancer34. Gupta et al. did not find any significant differences in adverse pathologic outcomes or 256 
BCR or MFS comparing those treated within 3 month to those waiting 3-6 months35. Gleason 257 
Group 5 patients primarily underwent RP at <3 mo. (87%). Patel et al also found 6 months to be 258 
an acceptable delay, but acknowledges that to evaluate the data, Grade Group 3,4,and 5 were 259 
included together as high-risk patients36. Fossati et al. studied 2,653 patients that had undergone 260 
RP and found that 283 patients experienced BCR and 84 patients developed clinical recurrence 261 
(CR)37. Furthermore, patients with highest risk started to experience higher rates of BCR and CR 262 
after 12 months of surgical treatment delay. Similarly, most high-risk patients were treated 263 
within 12 months (386 patients) and 208 patients were treated within 3 months. Only a total of 264 
17 patients were treated after 12 months delay. 265 
The role of neoadjuvant therapies may play a role in higher risk prostate cancer. A 266 
randomized study for neoadjuvant hormonal therapy (NHT) demonstrated that patients 267 
undergoing 12 weeks of cyproterone acetate tended to have prostatectomy specimens with lesser 268 
weights, smaller tumor volumes, and greater Gleason scores. There were significantly fewer 269 
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positive margin rates in patients undergoing NHT (27.7% vs. 64.8%, p<0.01). Interestingly, 270 
treated patients had higher rates of seminal vesicle involvement (27.7% vs 14.3%, P<0.05)38. 271 
Patients followed for 36 months showed no difference between the two groups in terms of 272 
biochemical progression, and at long-term follow up (median time 6 years), there was a 273 
biochemical recurrence-free survival benefit in patients with initial PSA greater than 20ng/ml 274 
that had received NHT38. Another long-term study followed 354 patients who received Goserelin 275 
and Flutamide for 3 months39. In the initial studies, patients undergoing NHT demonstrated 276 
improved pathological outcomes after RP. These patients were then followed over 4 years, and 277 
patients with cT2 tumors showed lower local recurrence rates in patients undergoing NHT. 278 
However, this finding was not present in the cT3 group. Although there were fewer positive 279 
margin rates in the initial study, the NHT cohort did not necessarily translate to better PSA 280 
progression rates after 4 years of follow up39. Of note, Meyer et al. did find that patients 281 
receiving more than 3 months of NHT prior to RP had a lower risk of PSA failure compared to 282 
patients receiving only surgery without NHT at the 5-year mark40. 283 
Lastly, recent studies have compared patients neoadjuvant chemohormonal therapy 284 
(NCHT) with RP to high risk (>cT3a, Gleason 8-10, PSA > 50ng/ml, or pelvic metastatic 285 
involvement) patients only undergoing RP or RP with NCHT. Patients receiving NCHT 286 
(docetaxel-based) combined with RP were more likely to achieve undetectable postoperative 287 
PSA as well as more favorable surgical pathology with organ confined disease and less pT3 or 288 
pT4 disease41. Biochemical recurrence also occurred earlier in the untreated group (9 months vs 289 
13 months biochemical PFS). In the latest CALGB 90203 Phase III randomized study of patients 290 
undergoing NCHT and RP to patients having RP alone, the NCHT group had lower pathologic 291 
T-stage, lower likelihood of seminal vesicle invasion, positive lymph nodes, or positive surgical292 
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margins42.The survival outcome remains to be studied. It remains important to note that 293 
treatment with NCHT is associated with adverse side effects such as immunosuppression. 294 
Discussion: For prostate cancer, the literature provides significant variability in safe 295 
delay times. Some found delays of 60 days can affect recurrence free survival, whereas other 296 
studies found no survival outcome differences up to 12 months. Studies finding that longer 297 
delays were feasible may be the fact that most high-risk patients were treated within 3 months. 298 
Studies have also demonstrated that a 3-month course of NHT does not negatively impact long-299 
term survival and would allow patients to safely delay surgery. We recommend consideration of 300 
neoadjuvant therapy in high-risk patients that may have prolonged delay (Table 1). In terms of 301 
diagnosing prostate cancer, patients with higher risk of prostate cancer based on PSA, age, 302 
physical exam and other adjunctive screens should preferentially be biopsied. 303 
Adrenal Cancer 304 
Adrenocortical Carcinoma (ACC) is an aggressive malignancy, the median disease 305 
specific survival (DSS) of ACC is 34 months and 5-year DSS is 39% from a study of patients 306 
with localized primary disease43. Meyer et al. followed 20 patients that underwent operative 307 
treatment for adrenal cortical carcinoma44. From this cohort, Stage I and II had mean survival for 308 
65 months compared to Stage III which was 38 months and Stage IV which was 19 months. The 309 
5-year survival rate was 23%. Neoadjuvant therapy for adrenocortical carcinoma demonstrating310 
significant differences in clinical outcomes is lacking. Adrenocortical carcinoma is an aggressive 311 
disease that needs complete surgical resection, if feasible, to achieve improved survival rates. 312 
Studies found patients that underwent resection of localized disease had median survival of 101 313 
months for Stage 1 and Stage 2 tumors45. 314 
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Discussion: Patients should be prioritized in surgical treatment of adrenal cancer (Table 315 
1). 316 
Testicular Cancer 317 
Testicular cancer primarily affects younger men and any issues with management can 318 
have lasting effects. Any significant delay (4-6 months) in diagnosis of testicular cancer 319 
increased the probability of metastatic disease - 20% of patients with a delay <30 days had 320 
metastasis compared to 55% of patients with a delay >4-months46. 321 
After diagnosis, patients with clinical stage I or clinical stage II would need to consider 322 
management options, including primary retroperitoneal lymph node dissection (P-RPLND). For 323 
Stage I tumors, surveillance is a feasible choice during the pandemic, even for patients with high 324 
risk features 47. Similarly, patients with Stage II tumors that may be amenable to RPLND will 325 
need to be counseled, and their final decision on surgery may depend on person preferences and 326 
hospital resources. Furthermore, chemotherapy may cause immediate side effects such as nausea, 327 
vomiting, nephrotoxicity but also lasting issues such as hypogonadism, infertility, pulmonary 328 
toxicity, cardiovascular disease, secondary malignancies, and neuropathy48. In reviewing the 329 
literature, the topic of delaying post-chemotherapy retroperitoneal lymph node dissection is 330 
lacking. 331 
 Discussion: Based on this data, patients with testicular cancer would likely benefit with 332 
minimized delays and diagnosis with orchiectomy should try to be prioritized. Whether patients 333 
choose chemotherapy, surgery, or surveillance for Stage II disease should be a multidisciplinary 334 
approach (Table 1). 335 
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Penile Cancer 336 
Even outside of a pandemic, current literature describes that patients with penile cancer 337 
may experience delays in receiving medical care. In one study by Gao et al. of 254 patients, the 338 
average delay from initial symptoms to initial consultation was 116 days (SD=17.2)49. Patients 339 
that had delays in care demonstrated issues with sexual function at the 3-month mark, and 340 
patients with delays of greater than 6 months had significantly worse survival outcomes. In terms 341 
of the pathological effects, patients with a 3-month delay were found to have worse surgical 342 
pathology. Chipollini et al. retrospectively reviewed patients that had delays in care from time of 343 
primary surgery to inguinal lymph node dissection (ILND)50. In terms of RFS, ILND within 3 344 
months had rates of 77% at 5-year RFS compared to 37.8% for > 3-month delay. For 5-year 345 
DSS, early resection < 3 months was 64.1% compared to 39.5% for > 3 months. This was further 346 
subdivided based on aggressiveness of disease. In patients with cN0 disease, 5-year DSS was 347 
78.6% for patients that had undergone resection in < 3 months and 45.8% for patients 348 
undergoing ILND > 3 months. Patients with more aggressive disease (cN+) 5-year DSS was 349 
31.8% (< 3 months) compared to 35.3% (> 3 months). 350 
Discussion: Since many penile cancer patients already experience delay for initial 351 
consultation, early surgical care is important for these patients to optimize both sexual function 352 
and survival outcomes with resectable disease (Table 1). 353 
354 
355 
356 
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Conclusion 357 
COVID-19 has significantly altered the management of urologic cancers. With the 358 
possibility of another surge with COVID-19, critical analysis of the literature on surgical delay 359 
can guide timing of treatment to minimize risk to the patient and hospital resources. 360 
361 
362 
363 
364 
365 
366 
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Table 1. Recommendations on urologic cancer from review of literature during the COVID-19 
pandemic 
Urologic Cancer Recommendation 
Bladder Cancer MIBC: Minimize delay to surgery especially 
high risk and variant histology. Neoadjuvant 
therapy should be considered. 
NMBIC: Appropriately counsel patients on 
intravesical therapy based on risk of disease. 
Delay in TURBT can lead to worse prognosis, 
especially in higher risk cases. Early imaging 
and screening cystoscopy are important to 
identify burden of disease. 
Renal Cancer T1a: patients can be followed with active 
surveillance 
T1b: delaying surgical intervention is 
appropriate 
≥T2: consider urgent surgery if patients have 
unfavorable pre-operative characteristics on 
imaging or biopsy. 
Locally Advanced/Metastatic RCC: Systemic 
therapy may benefit and allow safe surgical 
delay. This may also help identify patients 
that would benefit most from cytoreductive 
nephrectomy. Prefer oral therapy rather than 
IV/immune checkpoint inhibitors. 
Prostate Cancer Low risk prostate cancer – no significant 
effect with prolonged delays 
Higher risk prostate cancer: Likely can delay 
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for several months. Can recommend 
neoadjuvant hormonal therapy. Risks 
associated with neoadjuvant chemohormonal 
therapy. 
Penile Cancer ILND: should undergo without significant 
delay from time of penectomy. 
Penectomy: delays can affect sexual function, 
can be done as outpatient. 
Testis Cancer Orchiectomy: should be done as outpatient 
and avoid significant delay in diagnosis 
Primary RPLND: other choices available 
depending on clinical stage. Multidisciplinary 
approach with urologist and oncologist. 
Post-chemo RPLND: should not undergo any 
delay. 
UTUC High risk: should undergo surgery, without 
delay, especially in ureter 
Low risk: delay should not have significant 
effect on surgical outcomes 
Thorough evaluation should be performed to 
assess disease burden prior to consideration of 
delaying secondary procedures. 
Adrenal Cancer Should undergo surgical resection, relatively 
poor prognosis 
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